The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), was held on Thursday May 4, 2017 at 3.00 p.m. in Wallenbergsalen, the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is available for download under "Related Documents" on this page.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,794,687,847.
The board members and the chief executive officer were discharged from liability for the financial year 2016.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Shikan were re-elected for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Principles for remuneration for the management, long-term incentive program, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 496,760 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,497,125 own common shares to program participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 158,563 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2014, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to "Related Documents" on this page.